ZURICH (Reuters) – Novartis is still helping CureVac make COVID-19 vaccines and could expand its capacity to assist other vaccine manufacturers as well, finance chief Harry Kirsch told reporters on Wednesday.
“We have started the production as planned. We are planning to deliver 50 million doses this year,” Kirsch said of the CureVac deal when asked whether it could instead make its capacity free for others after CureVac said last month its COVID-19 jab was only 48% effective.
Swiss drugmaker Novartis also assists Pfizer and BioNTech in making COVID-19 vaccines and can ramp up output for them or others if needed, he said.
(Reporting by Michael Shields and Patricia Weiss, editing by John Revill)
